Oxford University Receives $12.3M to Study Medical Cannabis
One of the world’s top research universities, Oxford University, has received 10 million pounds ($12.3 million) from a London-based private equity firm to study the medical benefits of marijuana, a move that could lead to more acceptance of MMJ as a medicinal therapy worldwide.
According to a news release, Oxford will use the money to identify state-of-the-art medical therapy by researching the “molecular, cellular and system mechanisms of cannabinoids.”
Citing pain, cancer and inflammatory disease, the release noted the British university will target therapies for acute and chronic conditions.
Kingsley Capital Partners, which is providing the funding, has plowed investment dollars into the therapeutic cannabinoid market.
Kingsley plans to bankroll Oxford’s research effort through a new portfolio company, Oxford Cannabinoid Technologies. The program is funded over 36 months.
Oxford and Kingsley plan to host an International Cannabinoid Biomedicine Conference intended “to increase dialogue in the cannabinoid research space.” The first gathering is scheduled for the fourth quarter of 2017.
This article first appeared on Marijuana Business Daily.
Veteran Says Medical Marijuana Controls His PTSD Symptoms: Wants Cannabis For All Vets
Some of the latest statistics show that somewhere around 20 percent of the military veterans that se…
Medical Cannabis Use May Be Legalized in Greece
The Health Ministry in Greece is set to propose changes to legislation covering the use and producti…
Mother Of Teen With Tourette’s Pushes For Medical Cannabis In Schools
Since the passage of the medical marijuana bill in Minnesota, patients across the state have been he…
Medical Marijuana Use Rejected for Intractable Pain & Autism
The Illinois Department of Public Health has rejected intractable pain and autism spectrum disorder …
Cannabidiol reverses the mCPP-induced increase in marble-burying behavior
Cannabidiol (CBD), one of the main components of Cannabis sp., presents clinical and preclinical anx…
Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
Cannabidiol, a nonpsychoactive constituent of the Cannabis sativa plant, has been reported to act as…